Selected article for: "acute ards and lung cancer"
Author: Razavi, AzadehSadat; Hamblin, Michael R.; Rezaei, Nima
Title: COVID-19 in patients with cancer: Risks and precautions
  • Cord-id: c01anez1
  • Document date: 2021_1_28
    • ID: c01anez1
    Snippet: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a member of the coronavirus family, which causes coronavirus disease 2019 (COVID-19). The phenotype of the disease varies from asymptomatic, to a mild phenotype, through to the severe form of acute respiratory distress syndrome (ARDS), which often leads to death, especially in those with underlying diseases. It has been reported that those who suffer from cancer (especially lung cancer and hematological malignancies) are at higher r
    Document: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a member of the coronavirus family, which causes coronavirus disease 2019 (COVID-19). The phenotype of the disease varies from asymptomatic, to a mild phenotype, through to the severe form of acute respiratory distress syndrome (ARDS), which often leads to death, especially in those with underlying diseases. It has been reported that those who suffer from cancer (especially lung cancer and hematological malignancies) are at higher risk of serious complications and death from COVID-19. Some cancer treatments such as CAR T cell therapy can produce a cytokine storm, which is also a hallmark of severe COVID-19. Therefore, patients receiving CAR T cells are at higher risk if they become infected with COVID-19, and could be treated with anti-cytokine approaches.

    Search related documents:
    Co phrase search for related documents
    • active treatment and long persistence: 1, 2
    • active treatment and lung cancer: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • active treatment and lung cancer patient: 1
    • active treatment and lung epithelial cell: 1
    • active treatment and lung tumor: 1, 2, 3, 4, 5
    • active treatment and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute ards respiratory distress syndrome and long persistence: 1
    • acute ards respiratory distress syndrome and lung cancer: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute ards respiratory distress syndrome and lung cancer patient: 1
    • acute ards respiratory distress syndrome and lung dysfunction: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
    • acute ards respiratory distress syndrome and lung epithelial cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute ards respiratory distress syndrome and lung tumor: 1, 2
    • acute ards respiratory distress syndrome and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and lymphopenia lead: 1
    • acute ards respiratory distress syndrome and lymphopenia patient: 1
    • lung cancer and lymphocyte count: 1, 2, 3, 4, 5
    • lung dysfunction and lymphocyte count: 1, 2
    • lung tumor and lymphocyte count: 1